These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 12459644)

  • 1. Clinical and histopathological features of malignant melanoma in germline CDKN2A mutation families.
    Måsbäck A; Olsson H; Westerdahl J; Sandberg T; Borg A; Jonsson N; Ingvar C
    Melanoma Res; 2002 Dec; 12(6):549-57. PubMed ID: 12459644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and histologic characteristics of malignant melanoma in families with a germline mutation in CDKN2A.
    van der Rhee JI; Krijnen P; Gruis NA; de Snoo FA; Vasen HFA; Putter H; Kukutsch NA; Bergman W
    J Am Acad Dermatol; 2011 Aug; 65(2):281-288. PubMed ID: 21570156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations.
    Goldstein AM; Struewing JP; Chidambaram A; Fraser MC; Tucker MA
    J Natl Cancer Inst; 2000 Jun; 92(12):1006-10. PubMed ID: 10861313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations of 9p21 variants with cutaneous malignant melanoma, nevi, and pigmentation phenotypes in melanoma-prone families with and without CDKN2A mutations.
    Yang XR; Liang X; Pfeiffer RM; Wheeler W; Maeder D; Burdette L; Yeager M; Chanock S; Tucker MA; Goldstein AM
    Fam Cancer; 2010 Dec; 9(4):625-33. PubMed ID: 20574843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency of UV-inducible NRAS mutations in melanomas of patients with germline CDKN2A mutations.
    Eskandarpour M; Hashemi J; Kanter L; Ringborg U; Platz A; Hansson J
    J Natl Cancer Inst; 2003 Jun; 95(11):790-8. PubMed ID: 12783933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer risks and survival in patients with multiple primary melanomas: Association with family history of melanoma and germline CDKN2A mutation status.
    Helgadottir H; Tuominen R; Olsson H; Hansson J; Höiom V
    J Am Acad Dermatol; 2017 Nov; 77(5):893-901. PubMed ID: 28818438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample.
    Begg CB; Orlow I; Hummer AJ; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Mitra N; Busam K; From L; Berwick M;
    J Natl Cancer Inst; 2005 Oct; 97(20):1507-15. PubMed ID: 16234564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melanoma-prone families: new evidence of distinctive clinical and histological features of melanomas in CDKN2A mutation carriers.
    Gironi LC; Colombo E; Pasini B; Giorgione R; Farinelli P; Zottarelli F; Esposto E; Zavattaro E; Allara E; Ogliara P; Betti M; Dianzani I; Savoia P
    Arch Dermatol Res; 2018 Dec; 310(10):769-784. PubMed ID: 30218143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDKN2A mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanomas and other neoplasia.
    Ruiz A; Puig S; Malvehy J; Lázaro C; Lynch M; Gimenez-Arnau AM; Puig L; Sánchez-Conejo J; Estivill X; Castel T
    J Med Genet; 1999 Jun; 36(6):490-3. PubMed ID: 10874641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas.
    Hashemi J; Platz A; Ueno T; Stierner U; Ringborg U; Hansson J
    Cancer Res; 2000 Dec; 60(24):6864-7. PubMed ID: 11156381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melanoma and nonmelanoma skin cancer in patients with multiple tumours--evidence for new syndromes in a population-based study.
    Nielsen K; Ingvar C; Måsbäck A; Westerdahl J; Borg A; Sandberg T; Jonsson N; Nagel J; Olsson H
    Br J Dermatol; 2004 Mar; 150(3):531-6. PubMed ID: 15030338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variation in Cutaneous Patterns of Melanomagenesis According to Germline CDKN2A/CDK4 Status in Melanoma-Prone Families.
    Sargen MR; Pfeiffer RM; Yang XR; Tucker MA; Goldstein AM
    J Invest Dermatol; 2020 Jan; 140(1):174-181.e3. PubMed ID: 31326397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surveillance of second-degree relatives from melanoma families with a CDKN2A germline mutation.
    van der Rhee JI; Boonk SE; Putter H; Cannegieter SC; Flinterman LE; Hes FJ; de Snoo FA; Mooi WJ; Gruis NA; Vasen HF; Kukutsch NA; Bergman W
    Cancer Epidemiol Biomarkers Prev; 2013 Oct; 22(10):1771-7. PubMed ID: 23897584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors predicting the occurrence of germline mutations in candidate genes among patients with cutaneous malignant melanoma from South Italy.
    Casula M; Colombino M; Satta MP; Cossu A; Lissia A; Budroni M; Simeone E; Calemma R; Loddo C; Caracò C; Mozzillo N; Daponte A; Comella G; Canzanella S; Guida M; Castello G; Ascierto PA; Palmieri G;
    Eur J Cancer; 2007 Jan; 43(1):137-43. PubMed ID: 17055252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The CDKN2A tumour suppressor gene: no mutations detected in patients with melanoma and additional unrelated cancers.
    Alao JP; Mohammed MQ; Retsas S
    Melanoma Res; 2002 Dec; 12(6):559-63. PubMed ID: 12459645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline CDKN2A Mutation Status and Survival in Familial Melanoma Cases.
    Helgadottir H; Höiom V; Tuominen R; Nielsen K; Jönsson G; Olsson H; Hansson J
    J Natl Cancer Inst; 2016 Nov; 108(11):. PubMed ID: 27287845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDKN2A mutations in multiple primary melanomas.
    Monzon J; Liu L; Brill H; Goldstein AM; Tucker MA; From L; McLaughlin J; Hogg D; Lassam NJ
    N Engl J Med; 1998 Mar; 338(13):879-87. PubMed ID: 9516223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the CDKN2A locus in patients with multiple primary melanomas.
    Puig S; Malvehy J; Badenas C; Ruiz A; Jimenez D; Cuellar F; Azon A; Gonzàlez U; Castel T; Campoy A; Herrero J; Martí R; Brunet-Vidal J; Milà M
    J Clin Oncol; 2005 May; 23(13):3043-51. PubMed ID: 15860862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CDKN2A mutation and deletion status in thin and thick primary melanoma.
    Cachia AR; Indsto JO; McLaren KM; Mann GJ; Arends MJ
    Clin Cancer Res; 2000 Sep; 6(9):3511-5. PubMed ID: 10999737
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Pissa M; Helkkula T; Appelqvist F; Silander G; Borg Å; Pettersson J; Lapins J; Nielsen K; Höiom V; Helgadottir H
    Acta Oncol; 2021 Jul; 60(7):888-896. PubMed ID: 33945383
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.